Drugs / sodium stibogluconate
sodium stibogluconate
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01009502 | Jul 2009 → Mar 2012 | myelodysplastic syndrome | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT00498979 | May 2007 → May 2010 | melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00629200 | Sep 2006 → Feb 2010 | cancer of unknown primary site | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00311558 | Oct 2005 → May 2011 | cancer | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00657618 | Oct 2004 → Apr 2010 | leishmaniasis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04906031 | Jun 2020 → Feb 2023 | acute myeloid leukemia, myelodysplastic syndrome | First Affiliated Hospital of Jinan University | Unknown | No outcome recorded |
| Phase 2 | NCT01067443 | Mar 2010 → Jun 2011 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 2 | NCT00662012 | Jun 2002 → Oct 2007 | leishmaniasis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00508963 | — | cutaneous leishmaniasis, mucocutaneous leishmaniasis | University of California, San Francisco | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 10 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT06798402 Comparator | Feb → Nov 2025 overdue | cutaneous leishmaniasis | Al-Mustafa University College | Recruiting | No outcome recorded |
| Phase 2 | NCT05957978 Comparator | Mar 2024 → Jun 2025 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 2 | NCT00996463 Comparator | Jan → Sep 2010 | — | Waisenmedizin e. V. Promoting Access to Essential Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01011309 Comparator | Oct 2009 → May 2011 | cutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 2 | NCT00884377 Comparator | Feb 2004 → Jan 2009 | cutaneous leishmaniasis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07463040 Comparator | Jan 2027 → Mar 2029 expected | cutaneous leishmaniasis | Institute of Tropical Medicine, Belgium | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05708625 Comparator | Jan 2022 → Dec 2023 | cutaneous leishmaniasis | Zagazig University | Unknown | No outcome recorded |
| Phase 3 | NCT03129646 Comparator | Jan 2018 → Dec 2020 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 3 | NCT00255567 Comparator | Nov 2004 → Jan 2010 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01661296 Comparator | Aug 2009 → Aug 2011 | cutaneous leishmaniasis | Sarder Patel Medical College | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium stibogluconate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00884377 ↗ |
| Known as | Pentostam | “Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).” NCT00508963 ↗ |
| Known as | SSG | “Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.” PMID 22724029 ↗ Jun 20126“miltefosine, sodium stibogluconate (SSG) or liposomal amphotericin B” PMID 21718522 ↗ Jun 2011 “received intradermal sodium stibogluconate (SSG) (Group I)” PMID 25420793 ↗ Nov 2014 “sodium stibogluconate (SSG)” NCT00311558 ↗ “Sodium Stibogluconate (SSG)” NCT07463040 ↗ “Sodium Stibogluconate (SSG)” NCT00657618 ↗ “Sodium Stibogluconate (SSG)” NCT00662012 ↗ |
| Action | Inhibit | “Define the effectiveness of SSG in inhibiting the protein tyrosine phosphatases src homology proteins (SHP)-1 and SHP-2” NCT00311558 ↗ |
| Route | Intravenous | “SSG IV over 15 minutes” NCT00311558 ↗ |